Drug Profile
Botulinum toxin E - AbbVie
Alternative Names: AGN 151586; BoNT/E; BoNTE; EB-001; EB-001A; EB-001TLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Bonti
- Developer AbbVie
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents; SNARE protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Glabellar lines
- No development reported Musculoskeletal pain; Scars
Most Recent Events
- 13 Mar 2024 AbbVie plans a phase III trial in Glabellar lines in China, Taiwan, and Japan (IM) in June 2024 (NCT06308198)
- 04 Dec 2023 Phase-I/II clinical trials in Glabellar lines in Japan (IM) (NCT06151561)
- 30 Nov 2023 AbbVie plans a phase I/II trial for Glabellar Lines in Japan (IM, injection) (NCT06151561)